ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
105.93
-0.33 (-0.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close106.26
Open106.33
Bid104.00 x 600
Ask109.00 x 200
Day's Range105.75 - 108.07
52 Week Range70.76 - 153.99
Volume373,012
Avg. Volume736,841
Market Cap10.648B
Beta3.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $674 million.

  • How Analysts Are Rating Puma Biotechnology in July
    Market Realist14 days ago

    How Analysts Are Rating Puma Biotechnology in July

    The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga16 days ago

    Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

    Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's ...

  • Why This Biotech Company 'Dominates' Its Rival In Drug Study
    Investor's Business Daily17 days ago

    Why This Biotech Company 'Dominates' Its Rival In Drug Study

    Alnylam seemingly outperformed rival Ionis in tests of drugs to treat a progressive rare disease, an analyst said Thursday. Both biotech companies are making treatments for a condition known as hereditary ATTR amyloidosis.

  • Medicines Company's Inclisiran Studies to Continue Unmodified
    Zacks24 days ago

    Medicines Company's Inclisiran Studies to Continue Unmodified

    The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.

  • Caladrius Biosciences’ Stock Price Rose 67% on June 19
    Market Realistlast month

    Caladrius Biosciences’ Stock Price Rose 67% on June 19

    On June 19, Caladrius Biosciences’ stock price rose 67.3% and reached $6.61 from the previous close of $3.95 on June 18.

  • Alnylam Reports Positive Data on Lumasiran in Renal Disease
    Zackslast month

    Alnylam Reports Positive Data on Lumasiran in Renal Disease

    Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • 3 Top Biotech Stocks to Buy in June
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy in June

    The cure for your portfolio's ills might be found in these three mid-cap biotech stocks.

  • Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?
    Zacks2 months ago

    Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.
    Motley Fool2 months ago

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.

    Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner?

  • The Upside Potential in Editas Medicine Stock
    Market Realist2 months ago

    The Upside Potential in Editas Medicine Stock

    Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

  • Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
    Market Realist2 months ago

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.

  • What Do Alnylam’s Valuations Indicate?
    Market Realist2 months ago

    What Do Alnylam’s Valuations Indicate?

    Alnylam Pharmaceuticals’ (ALNY) interest income grew from $2.1 million in Q1 2017 to $5.8 million in Q1 2018. While the company had incurred other expenses of $2.9 million in Q1 2017, it earned $335,000 in other income in Q1 2018.

  • How Has Alnylam Pharmaceuticals Performed Financially?
    Market Realist2 months ago

    How Has Alnylam Pharmaceuticals Performed Financially?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) generated collaboration revenues of $21.9 million in Q1 2018 compared with $18.9 million in Q1 2017. The company earns the majority of its collaboration revenues from Sanofi Genzyme and MDCO.

  • Why Alnylam’s Clinical Pipeline Seems Promising
    Market Realist2 months ago

    Why Alnylam’s Clinical Pipeline Seems Promising

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals’ (ALNY) target indications include genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. Alnylam Pharmaceuticals aims to have three products on the market and ten RNAi therapeutic clinical programs by the end of 2020.

  • Alnylam Pharmaceuticals: Banking on Strategic Collaborations
    Market Realist2 months ago

    Alnylam Pharmaceuticals: Banking on Strategic Collaborations

    Alnylam Pharmaceuticals (ALNY) has formed key alliances with leading pharmaceutical and life sciences players to support its development and commercialization activities. These include Sanofi Genzyme, the specialty care global business unit of Sanofi, the Medicines Company (or MDCO), and Vir Biotechnology. Additionally, in late 2017, Alnylam Pharmaceuticals joined a research consortium with UK Biobank, Regeneron Pharmaceuticals, and four other pharmaceutical companies aimed at generating 500,000 human exome sequences linked to medical records by the end of 2019. ...

  • Exploring Alnylam Pharmaceuticals’ Clinical Programs
    Market Realist2 months ago

    Exploring Alnylam Pharmaceuticals’ Clinical Programs

    Alnylam Pharmaceuticals (ALNY) presented updated phase one data for ALN-TTRsc02 in March 2018. ALN-TTRsc02 is a subcutaneously administered investigational RNAi therapeutic under development for treating ATTR amyloidosis. The drug received a positive opinion from the European Medicines Agency (or EMA) committee for orphan medicinal products for orphan drug designation in the European Union.

  • Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
    Market Realist2 months ago

    Analyst Views on the Upside Potential of Alnylam Pharmaceuticals

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.

  • Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
    Motley Fool2 months ago

    Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?

    Good news for Pfizer muddies the waters somewhat for Alnylam's outlook.

  • BioMarin Begins Mid Stage Study on Gene Therapy Candidate
    Zacks2 months ago

    BioMarin Begins Mid Stage Study on Gene Therapy Candidate

    BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Looks Forward
    Motley Fool2 months ago

    Alnylam Looks Forward

    An uneventful earnings release as the company anticipates an approval of its hereditary TTR amyloidosis drug, patisiran.